Brexit isn’t just causing shortages in Sainsburys in Essex, it’s damaging our Pharmaceutical sector too.
14th July 2022:
UK approved fewer new drugs than EU and US in year after Brexit transition
Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers
“The UK approved fewer new medicines than the EU and the US in 2021, the first year after the end of the
Brexit transition period, researchers at Imperial College London have found.
Their analysis shows that only 35 new drugs were approved for use in the UK by the country’s medicines regulator last year, compared with 40 approvals in the EU and 52 in the US.
Members of the academic community warned that there could be negative knock-on effects for the UK’s role in scientific research and development (R&D).
Steve Bates, chief executive of the UK’s BioIndustry Association, said the Imperial analysis was a “wake-up call” for the UK, and stressed the need for the regulator to work closely with the NHS and the National Institute for Health and Care Excellence (Nice), which recommends whether drugs should be available on the NHS”
Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers
www.theguardian.com